Beam Therapeutics Announced The First Patient Was Treated With BEAM-302, An Investigational In Vivo Base Editing Medicine Designed To Precisely Correct The Underlying Cause Of Severe Alpha-1 Antitrypsin Deficiency, Currently In Phase 1/2 Trial
Beam Therapeutics Announced The First Patient Was Treated With BEAM-302, An Investigational In Vivo Base Editing Medicine Designed To Precisely Correct The Underlying Cause Of Severe Alpha-1 Antitrypsin Deficiency, Currently In Phase 1/2 Trial
beam therapeutics宣佈，第一位接受BEAM-302治療的患者是嚴重的α-1抗胰蛋白酶缺乏症的病人，這是一種試驗性的原位基因編輯藥物，旨在精確糾正其潛在原因，目前處於1/2期試驗中。
Beam Therapeutics Announced The First Patient Was Treated With BEAM-302, An Investigational In Vivo Base Editing Medicine Designed To Precisely Correct The Underlying Cause Of Severe Alpha-1 Antitrypsin Deficiency, Currently In Phase 1/2 Trial
beam therapeutics宣佈，第一位接受BEAM-302治療的患者是嚴重的α-1抗胰蛋白酶缺乏症的病人，這是一種試驗性的原位基因編輯藥物，旨在精確糾正其潛在原因，目前處於1/2期試驗中。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。